Escherichia coli sequence type 131 as a prominent cause of antibiotic resistance among urinary Escherichia coli isolates from reproductive-age women

Journal of Clinical Microbiology

Volumn 51, Issue 10, 2013, Pages 3270-3276

  Kudinha, Timothy ^a,c   Johnson, James R ^b   Andrew, Scott D ^a   Kong, Fanrong ^c   Anderson, Peter ^a   Gilbert, Gwendolyn L ^c,d  

^a CHARLES STURT UNIVERSITY   (Australia)

^b UNIVERSITY OF MINNESOTA   (United States)

^c WESTMEAD HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFALOTIN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; NALIDIXIC ACID; NITROFURANTOIN; NORFLOXACIN; TETRACYCLINE;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUSTRALIA; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BIOFILM; CONTROLLED STUDY; CYSTITIS; ESCHERICHIA COLI; FECES ANALYSIS; FEMALE; HUMAN; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PYELONEPHRITIS; URINALYSIS; VIRULENCE FACTOR GENE;

ADOLESCENT; ADULT; BIOFILMS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; NEW SOUTH WALES; PREVALENCE; PROSPECTIVE STUDIES; URINARY TRACT INFECTIONS; VIRULENCE FACTORS; YOUNG ADULT;

EID: 84884806775     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01315-13     Document Type: Article

References (45)

1. Foxman B, Brown P. 2003. Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect. Dis. Clin. North Am. 17:227-241. (Pubitemid 36760181)
2. Bartoloni A, Bartalesi F, Mantella A, Dell'Amico E, Roselli M, Strohmeyer M, Barahona HG, Barrón VP, Paradisi F, Rossolini GM. 2004. High prevalence of acquired antimicrobial resistance unrelated to heavy antimicrobial consumption. J. Infect. Dis. 189:1291-1294. (Pubitemid 38457255)
3. Goettsch W, van Pelt W, Nagelkerke N, Hendrix MG, Buiting AG, Petit PL, Sabbe LJ, van Griethuysen AJ, de Neeling AJ. 2000. Increasing resistance of fluoroquinolones in Escherichia coli from urinary tract infections in The Netherlands. J. Antimicrob. Chemother. 46:223-228. (Pubitemid 30639291)
4. Williams DN, Sannes MR, Eckhoff AA, Peterson PK, Johnson JR, Sannes MR, San Román M, Mora N, Moya J. 2003. Antimicrobial resistance among Escherichia coli causing urinary tract infections in Costa Rica: a clinical dilemma. Int. J. Antimicrob. Agents 21:79-82.
5. Platell JL, Johnson JR, Cobbold RN, Trott DJ. 2011. Multidrug-resistant extraintestinal Escherichia coli of sequence type ST131 in animals and foods. Vet. Microbiol. 153:99-108.
6. Kudinha T, Johnson JR, Andrew SD, Kong F, Anderson P, Gilbert GL. 2013. Distribution of phylogenetic groups, sequence type ST131, and virulence- associated traits among Escherichia coli isolates from men with pyelonephritis or cystitis and healthy controls. Clin. Microbiol. Infect. 19:173-180.
7. Kudinha T, Johnson JR, Andrew SD, Kong F, Anderson P, Gilbert GL. 2013. Genotypic and phenotypic characterization of Escherichia coli isolates from children with urinary tract infection and from healthy carriers. Pediatr. Infect. Dis. J. 32:543-548.
8. Horcajada JP, Soto S, Gajewski A, Smithson A, Jiménez de Anta MT, Mensa J, Vila J, Johnson JR. 2005. Quinolone-resistant uropathogenic Escherichia coli strains from phylogenetic group B2 have fewer virulence factors than their susceptible counterparts. J. Clin. Microbiol. 43:2962-2964. (Pubitemid 40827987)
9. Johnson JR, Kuskowski MA, Owens K, Gajewski A, Winokur PL. 2003. Phylogenetic origin and virulence genotype in relation to resistance to fluoroquinolones and/or extended-spectrum cephalosporins and cephamycins among Escherichia coli isolates from animals and humans. J. Infect. Dis. 188:759-768. (Pubitemid 37115190)
10. Johnson JR, van der Schee C, Kuskowski MA, Goessens W, van Belkum A. 2002. Phylogenetic background and virulence profiles of fluoroquinolone- resistant clinical Escherichia coli isolates from the Netherlands. J. Infect. Dis. 186:1852-1856. (Pubitemid 35463521)
11. Moreno E, Prats G, Sabaté M, Pérez T, Johnson JR, Andreu A. 2006. Quinolone, fluoroquinolone and trimethoprim/sulfamethoxazole resistance in relation to virulence determinants and phylogenetic background among uropathogenic Escherichia coli. J. Antimicrob. Chemother. 57: 204-211. (Pubitemid 43160159)
12. Kai-Larsen Y, Lüthje P, Chromek M, Peters V, Wang X, Holm A, Kádas L, Hedlund KO, Johansson J, Chapman MR, Jacobson SH, Römling U, Agerberth B, Brauner A. 2010. Uropathogenic Escherichia coli modulates immune responses and its curli fimbriae interact with the antimicrobial peptide LL-37. PLoS Pathog. 6:e1001010. doi:10.1371/journal.ppat. 1001010.
13. Luthje P, Brauner A. 2010. Ag43 promotes persistence of uropathogenic Escherichia coli isolates in the urinary tract. J. Clin. Microbiol. 48:2316-2317.
14. Lidin-Janson G, Kaijser B, Lincoln K, Olling S, Wedel H. 1978. The homogeneity of the faecal coliform flora of normal school-girls, characterized by serological and biochemical properties. Med. Microbiol. Immunol. 164:247-253. (Pubitemid 8315221)
15. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing, 17th informational supplement. CLSI M100-S17. Clinical and Laboratory Standards Institute, Wayne, PA.
16. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial disk susceptibility tests for bacteria that grow aerobically; approved standard-tenth edition. CLSI document M02-A10. Clinical and Laboratory Standards Institute, Wayne, PA.
17. Rijavec M, Müller-Premru M, Zakotrik B, Zgur-Bertok D. 2008. Virulence factors and biofilm production among Escherichia coli strains causing bacteraemia of urinary tract origin. J. Med. Microbiol. 57:1329-1334.
18. Clermont O, Bonacorsi S, Bingen E. 2000. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl. Environ. Microbiol. 66:4555-4558.
19. Kudinha T, Kong F, Johnson JR, Andrew SD, Anderson P, Gilbert GL. 2012. Multiplex PCR-based reverse line blot assay for simultaneous detection of 22 virulence genes in uropathogenic Escherichia coli. Appl. Environ. Microbiol. 78:1198-1202.
20. Johnson JR, Clermont O, Menard M, Kuskowski MA, Picard B, Denamur E. 2006. Experimental mouse lethality of Escherichia coli isolates, in relation to accessory traits, phylogenetic group, and ecological source. J. Infect. Dis. 194:1141-1150. (Pubitemid 44547655)
21. Clermont O, Johnson JR, Menard M, Denamur E. 2007. Determination of Escherichia coli O types by allele-specific polymerase chain reaction: application to the O types involved in human septicemia. Diagn. Microbiol. Infect. Dis. 57:129-136. (Pubitemid 46135872)
22. Platell JL, Cobbold RN, Johnson JR, Heisig A, Heisig P, Clabots C, Kuskowski MA, Trott DJ. 2011. Commonality among fluoroquinoloneresistant sequence type ST131 extraintestinal Escherichia coli isolates from humans and companion animals in Australia. Antimicrob. Agents Chemother. 55:3782-3787.
23. Clermont O, Dhanji H, Upton M, Gibreel T, Fox A, Boyd D, Mulvey MR, Nordmann P, Ruppé E, Sarthou JL, Frank T, Vimont S, Arlet G, Branger C, Woodford N, Denamur E. 2009. Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J. Antimicrob. Chemother. 64:274-277.
24. Johnson JR, Menard M, Johnston B, Kuskowski MA, Nichol K, Zhanel GG. 2009. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob. Agents Chemother. 53:2733-2739.
25. Cagnacci S, Guako L, Debbia E, Schito GC, Marchese A. 2008. European emergence of ciprofloxacin-resistant Escherichia coli clonal groups O25: H4-ST131 and O15:K52:H1 causing community-acquired uncomplicated cystitis. J. Clin. Microbiol. 46:2605-2612.
26. Karlowsky JA, Kasloff S, Nichol KA, Hoban DJ, Zhanel GG. 2007. Genetic relatedness of multidrug-resistant Escherichia coli cultured from geographically diverse outpatient, midstream urine specimens. Diagn. Microbiol. Infect. Dis. 58:283-287. (Pubitemid 47017638)
27. Johnson JR, Kuskowski MA, Gajewski A, Sahm DF, Karlowsky JA. 2004. Virulence characteristics and phylogenetic background of multidrug-resistant and antimicrobial-susceptible clinical isolates of Escherichia coli from the United States, 2000-2001. J. Infect. Dis. 190:1739-1744. (Pubitemid 39487816)
28. Starcic Erjavec M, Rijavec M, Krizan-Hergouth V, Fruth A, Zgur-Bdertok D. 2007. Chloramphenicol-and tetracycline-resistant uropathogenic Escherichia coli (UPEC) exhibit reduced virulence potential. Int. J. Antimicrob. Agents 30:436-442. (Pubitemid 47498963)
29. Lavigne JP, Vergunst AC, Goret L, Sotto A, Combescure C, Blanco J, O'Callaghan D, Nicolas-Chanoine MH. 2012. Virulence potential and genomic mapping of the worldwide clone Escherichia coli ST131. PLoS One 3:e34294. doi:10.1371/journal.pone.0034294.
30. Johnson JR, Porter SB, Zhanel G, Kuskowski MA, Denamur E. 2012. Virulence of Escherichia coli clinical isolates in a murine sepsis model in relation to sequence type ST131 status, fluoroquinolone resistance, and virulence genotype. Infect. Immun. 80:1554-1562.
31. Karlowsky JA, Hoban DJ, Decorby MR, Liang NM, Zhanel GG. 2006. Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance Study. Antimicrob. Agents Chemother. 50:2251-2254. (Pubitemid 43807558)
32. Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. 2010. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin. Infect. Dis. 51:286-294.
33. Johnson JR, Johnston B, Clabots C, Kuskowski MA, Pendyala S, DebRoy C, Nowicki B, Rice J. 2010. Escherichia coli sequence type 131 as an emerging fluoroquinolone-resistant uropathogen among renal transplant recipients. Antimicrob. Agents Chemother. 54:546-550.
34. Leflon-Guibout V, Blanco J, Amaqdouf K, Mora A, Guize L, Nicolas-Chanoine MH. 2008. Absence of CTX-M enzymes but high prevalence of clones, including clone ST131, among fecal Escherichia coli isolates from healthy subjects living in the area of Paris, France. J. Clin. Microbiol. 46:3900-3905.
35. Rogers BA, Sidjabit HE, Paterson DL. 2011. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J. Antimicrob. Chemother. 66:1-14.
36. Matsumura Y, Yamamoto M, Nagao M, Hotta G, Matsushima A, Ito Y, Takakura S, Ichiyama S, Kyoto-Shiga Clinical Microbiology Study Group. 2012. Emergence and spread of B2-ST131-O25b, B2-ST131-O16 and D-ST405 clonal groups among extended-spectrum-β-lactamaseproducing Escherichia coli in Japan. J. Antimicrob. Chemother. 67:2612-2620.
37. Cerquetti M, Giufrè M, García-Fernández A, Accogli M, Fortini D, Luzzi I, Carattoli A. 2010. Ciprofloxacin-resistant, CTX-M-15-producing Escherichia coli ST131 clone in extraintestinal infections in Italy. Clin. Microbiol. Infect. 16:1555-1558.
38. Uchida Y, Mochimaru T, Morokuma Y, Kiyosuke M, Fujise M, Eto F, Eriguchi Y, Nagasaki Y, Shimono N, Kang D. 2010. Clonal spread in Eastern Asia of ciprofloxacin-resistant Escherichia coli serogroup O25 strains, and associated virulence factors. Int. J. Antimicrob. Agents 35: 444-450.
39. Coque TM, Baquero F, Canton R. 2008. Increasing prevalence of ESBLproducing Enterobacteriaceae in Europe. Euro Surveill. 13:pii=19044. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19044.
40. CTX-M within an Australian extended-spectrum beta-lactamase gene pool. Antimicrob. Agents Chemother. 52:4198-4202.
41. Ramos NL, Dzung DT, Stopsack K, Jankó V, Pourshafie MR, Katouli M, Brauner A. 2011. Characterisation of uropathogenic Escherichia coli from children with urinary tract infection in different countries. Eur. J. Clin. Microbiol. Infect. Dis. 30:1587-1593.
42. Ruiz J, Simon K, Horcajada JP, Velasco M, Barranco M, Roig G, Moreno-Martínez A, Martínez JA, Jiménez de Anta T, Mensa J, Vila J. 2002. Differences in virulence factors among clinical isolates of Escherichia coli causing cystitis and pyelonephritis in women and prostatitis in men. J. Clin. Microbiol. 40:4445-4449. (Pubitemid 35434929)
43. Pan Y, Henderson J, Britt H. 2006. Antibiotic prescribing in Australian general practice: how has it changed from 1990-91 to 2002-03? Respir. Med. 100:2004-2011. (Pubitemid 44490281)
44. van de Sande-Bruinsma N, Grundmann H, Verloo D, Tiemersma E, Monen J, Goossens H, Ferech M, European Antimicrobial Resistance Surveillance System Group, European Surveillance of Antimicrobial Consumption Project Group. 2008. Antimicrobial drug use and resistance in Europe. Emerg. Infect. Dis. 14:1722-1730.
45. Mölstad S, Erntell M, Hanberger H, Melander E, Norman C, Skoog G, Lundborg CS, Söderström A, Torell E, Cars O. 2008. Sustained reduction of antibiotic use and low bacterial resistance: 10-year follow-up of the Swedish Strama programme. Lancet Infect. Dis. 8:125-132.